<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284514</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-9778-CI-OS-1001</org_study_id>
    <nct_id>NCT04284514</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution</brief_title>
  <official_title>Phase 1 Multi Center, Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single or Twice Daily Doses of AKB-9778 Ophthalmic Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerpio Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerpio Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics
      and pharmacodynamics of AKB-9778 ophthalmic solution (eye drops) administered for 7 days in
      adults. The study is a double-masked, multiple- ascending dose trial and will enroll four
      cohorts of up to 12 subjects. Dose cohorts will receive increasing doses of AKB-9778
      ophthalmic solution or vehicle-matched placebo daily for 7 days. Cohort 5 will enroll
      subjects with open angle glaucoma or ocular hypertension who will continue current
      prostaglandin therapy during the study. Cohort 5 subjects will receive the maximum tolerated
      dose from the previous cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Actual">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Baseline to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital sign- systolic and diastolic blood pressure</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Systolic and diastolic blood pressure in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>White blood cells with differential, hemoglobin, hematocrit and platelet count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Intraocular pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKB-9778 concentration</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Measurement of AKB-9778 in plasma after drug administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>AKB-9778 Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 4 daily dose levels of AKB-9778 Ophthalmic Solution will be evaluated. Doses will be administered in both eyes daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Control Ophthalmic Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched vehicle-control ophthalmic solution will be administered in both eyes daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKB-9778 Ophthalmic Solution</intervention_name>
    <description>AKB-9778 Ophthalmic Solution</description>
    <arm_group_label>AKB-9778 Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ophthalmic Solution</intervention_name>
    <description>Matched vehicle-control</description>
    <arm_group_label>Vehicle Control Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Aged &gt; 18 years to 70 years inclusive in Cohort 1; aged ≥ 45 to 70 years inclusive in
             Cohorts 2-4, aged 18 to 80 years inclusive in Cohort 5.

          -  For subjects in Cohort 1, IOP between 12 and 23 mm Hg (inclusive). For subjects in
             Cohorts 2-4, IOP between 16 and 23mm Hg (inclusive). For subjects in Cohort 5, IOP
             between 17 and 27 mm Hg (inclusive).

          -  Central corneal thickness of 480 to 600 μm, inclusive

          -  For subjects in Cohort 5, diagnosis of OAG or OHT

          -  For subjects in Cohort 5, currently receiving prostaglandin therapy for IOP lowering

        Key Exclusion Criteria:

          -  Diagnosis of any form of glaucoma in Cohorts 1-4

          -  Clinically significant eye trauma within 6 months of screening

          -  Any intraocular ophthalmic procedure within 6 months of screening

          -  Any ocular inflammation within 90 days of screening or a history of recurrent uveitis
             in either eye

          -  Subjects with any known chronic ocular disease (other than incipient cataract or
             refractive error)

          -  Any condition preventing valid applanation tonometry measurement, e.g., clinically
             significant corneal disease, refractive surgery

          -  Visual acuity (VA) worse than 20/30 in either eye, For Cohort 5 VA worse than 20/100
             in either eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

